ALVO News & Events

Alvotech announced key senior leadership changes following a planned succession process. Founder Robert Wessman, who has served as Chairman since the company's inception in 2013 and CEO since 2023, will transition out of the CEO role at the end of the first quarter of 2026. He will continue to serve as Executive Chairman in a full-time capacity. Lisa Graver has been appointed as his successor as CEO. She served as CEOO of Alvogen until its acquisition by Lotus Pharmaceutical in December 2025, and as a member of Alvotech's Board since its public listing in 2022. The transition process will begin immediately, with Ms Graver working closely with Mr Wessman and the executive team over the coming months to ensure continuity and a smooth handover. Upon assuming the CEO role, she will step down from the Alvotech Board.

Alvotech (ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical (TEVA) announced that they have reached a settlement and license agreement with Regeneron (REGN) concerning the launch of AVT06, Alvotech's proposed biosimilar to Eylea in the United States. The settlement grants a license entry date for AVT06 in the United States in the fourth quarter of 2026, or earlier under certain circumstances.